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Background: VEGF is one of the key drivers of physiological or pathological angiogenesis hence several VEGF
inhibitors are in different stages of clinical development. To further dissect the role of VEGF in different stages of
tumor progression in lung tumors, we utilized KrasG12D-LSL GEMMs (genetically engineered mouse models).
Methods: Intranasal delivery of adenoviruses expressing cre recombinase in KrasG12D-LSL mice results in the
expression of mutant Kras that leads to development of tumor lesions ranging from adenomatous hyperplasia to
large adenoma and adenocarcinoma over time in lung. In the current study, we treated KrasG12D-LSL mice at
14 weeks post inhalation with three different angiogenic inhibitors including axitinib and PF-00337210 both of
which are selective inhibitors of VEGFR and sunitinib which targets VEGFR, C-SF1-R, PDGFR and KIT.
Results: Pathology findings showed no significant difference in percentage of adenomatous hyperplastic lesions
between the vehicle vs. any of the treatments suggesting that angiogenesis may not play a major role at early
stages of tumorigenesis. However, each inhibitor suppressed percentage of benign adenoma lesions and almost
fully inhibited growth of adenocarcinoma lesions in the recipients which was consistent with a reduction in tumor
vasculature. Treatment with sunitinib which is a multi-targeted RTKI did not provide any advantage compared to
selective VEGFR inhibitor further emphasizing role of VEGF in tumor angiogenesis in this model.
Conclusion: Overall, our studies indicate significance of VEGF and angiogenesis in a spontaneous model of lung
tumorigenesis and provide a proof of mechanism for anti-cancer activity of VEGF inhibitors in this model.
Keywords: Lung cancer, Kinase and phosphatase inhibitors, Tumor angiogenesis, GEMM, VEGFBackground
Angiogenesis, formation of new blood vessels from
existing vasculature, is an important process that sup-
plies required nutrients and oxygen to cells which are
distant from existing blood vessels. Angiogenesis is
proven to play a key role in tumor growth and progres-
sion and several angiogenic factors such as VEGF (vas-
cular endothelial growth factor), PDGF (platelet derived
growth factor), bFGF (basic fibroblast growth factor) and
HGF (hepatocyte growth factor) found to be among key
regulators of tumor angiogenesis [1].* Correspondence: farbodshojaei@hotmail.com
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reproduction in any medium, provided the orSeries of investigations demonstrate a key role for
VEGF in physiological or pathological angiogenesis [1].
Hence, a number of anti-angiogenic drugs targeting
VEGF signaling pathway (ligand or the receptors) have
been developed and are currently in use in cancer
therapy. Bevacizumab (an anti-VEGF monoclonal anti-
body) was the first angiogenic inhibitor (hereafter AI)
initially approved for use in patients with NSCLC
(non-small cell lung cancer) or mCRC (metastatic
colorectal cancer) [2,3]. Small molecule inhibitors of re-
ceptor tyrosine kinase inhibitors (RTKIs) are another
class of agent targeting VEGF signaling pathway. RTKIs
such as sunitinib, sorafenib, cediranib, motesanib,
pazopanib and axitinib have been approved or are beingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which is a multi-targeted kinase inhibitor targets
VEGFRs, C-SF1R, KIT and also platelet-derived growth
factor (PDGFR) which plays an important role in blood
vessel maturation [4]. Recently, sunitinib was approved
by FDA for the treatment of advanced renal cell carcin-
oma, gastrointestinal stromal tumors and pancreatic
neuroendocrine tumors [5,6]. Axitinib (AG-013736;
Pfizer) is another oral potent tyrosine kinase inhibitor
which mainly targets VEGFR and was approved by
FDA for use in patients with advanced RCC [7]. In a
murine lewis lung carcinoma model, single agent axitinib
induced tumor necrosis and reduced microvessel density
[8]. PF-00337210 (hereafter PF-210) is an oral, potent ATP-
competitive inhibitor of VEGFR family [9]. It inhibits
VEGFR2 phosphorylation and has greater selectivity to-
wards VEGFR2 than other kinases. PF-210 has been shown
to inhibit HUVEC cell survival in vitro and suppresses
tumor angiogenesis in xenograft models [10].
Ras superfamily of proteins regulates cell growth, sur-
vival, and differentiation. Hras, Kras 4a, Kras 4b and
Nras are the four highly homologous proteins encoded
by three Ras genes [11,12]. Mutations in the KRAS gene
lead to KRas protein activation in many human tumors
including NSCLC, pancreatic cancer and colorectal can-
cer [12-14]. The majority of KRAS mutations (approxi-
mately 97%) occur in exon 2 at codon 12 and/or codon
13 in NSCLC patients [12]. The most common mutation
in KRAS occurs at position 12, where glycine is replaced
by a residue with side chain. NSCLC patients represent
the majority of all lung cancer patients and remain a
major cause of death [12]. Hence, KrasG12D-LSL GEMM
(genetically engineered mouse model) is one of the most
relevant models of NSCLC to study tumor progression
and to investigate efficacy of anti-cancer agents.
In the present study we investigated anti-tumor
efficacy of three RTKIs including sunitinib, axitinib
and PF-210 in KrasG12D-LSL lung tumor model. Irre-
spective of the type (multi-targeted or selective), all
three inhibitors significantly inhibited growth of ad-
vanced (adenocarcinoma) lesions in the lung indicating
that VEGF is a key regulator of tumor angiogenesis in
this model.
Methods
Tumor development and treatment in KrasG12D-LSL GEMMs
KrasG12D-LSL heterozygous mice were obtained from
Jackson Laboratories (Jax West, CA) at approximately
3–4 weeks of age and were maintained by Pfizer La Jolla
comparative medicine under guidelines provided by
IACUC (Institutional Animal Care and Use Committee).
Lung tumors were generated in KrasG12D-LSL mice, using
a recently published protocol [15]. Briefly, adenovirus
expressing Cre recombinase (Adeno-Cre;the Universityof Iowa Gene Transfer Vector Core, Iow, IA) were ti-
trated by Adenoviral Titration Kit (Clontech, CA) using
instruction provided by the manufacturer. Prior to ad-
ministration, Adeno-Cre virus was prepared in 50 ul of
plain MEM (minimal essential media; Gibco BRL; life
Sciences, CA) supplemented with CaCl2 (10 mM)
followed by incubation at room temperature (RT) for
20 minutes. The recipients (n = 10) were anesthetized
using Ketamine (Baxter) and Xylazine (Vedco) and the
adeno-Cre preparation (2.5 × 10^7 infectious units; IU)
was administered intra-nasally. To monitor tumor
formation and progression, lung tissue was isolated (n =
1-3) at several time points (4, 8 and 12 wks) post inhal-
ation and were stained with H&E (Hematoxylin and
Eosin) using standard protocols in the laboratory [15].
The inhaled mice were randomized at 14 wks post-
inhalation and were treated with vehicle, sunitinib
(40 mg/kg qd), axitinib (15 mg/kg bid) and PF-210
(40 mg/kg qd) using oral route of administration and
formulation protocols as described previously [8]. All
the animal study procedures were monitored by the vet-
erinary personnel to comply with guidelines provided by
IACUC.
To assess therapeutic response to angiogenic inhibi-
tors, lung lesions were quantified in the recipients by a
certified pathologist. As previously described, lesions
were categorized as hyperplastic, benign adenoma and
adenocarcinoma [15]. Lesion quantification provided
two types of analyses in the recipients: 1) percentage of
each type of lesion in the recipient lung; 2) percentage
of mice carrying these lesions in each treatment. To
provide statistical analyses, we applied student’s t test
(p < 0.05 considered significant) to compare data between
the vehicle vs. each treatment.
Histology
Formalin fixed paraffin embedded lung tissues were cut
into 5 μm sections and were stained for CD31, desmin,
and F4-80 separately. Immunohistochemical staining
was performed on Leica Bond III automated machine.
Bond polymer refine detection kit was used for desmin
and CD31 staining and bond intense R detection was
used for F4-80 staining. For CD31 staining, lung sections
were incubated for 45 minutes with rabbit anti-CD31
monoclonal antibody (clone SP38, Spring Bioscience,
cat # M3384, 1:100 dilution). Desmin was stained by in-
cubating lung section with mouse anti-huDesmin anti-
body (Dako Cytomation, cat# M0760, 1:1500 dilution)
for 15 minutes. VEGFR1 and VEGFR2 was stained
using anti-VEGFR1 antibody (abcam, cat# ab2350,
1:400 dilution) and anti-VEGFR2 antibody (cell signal-
ing, cat# 2479, 1:200 dilution) respectively. Finally,
F4-80 was stained with biotin anti-mouse F4-80 anti-
body (eBioscience, Cat # 13-4801-82, 1:75 dilution and
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slides were captured using a Nanozoomer instrument
(Hamamatsu, Japan) and the data was analyzed using
Aperio Imagescope software.Results
Targeting the VEGF pathway is sufficient to inhibit
progression of lung adenocarcinoma lesions in
KrasG12D-LSL mice
Our strategy to investigate anti-tumor efficacy of AIs in
KrasG12D-LSL mice is depicted in Figure 1A. KrasG12D-LSL
mice were inhaled intranasally with Adeno-Cre at 6–
8 weeks of age and were maintained without any further
intervention. At 8–10 weeks post inhalation, few mice













Figure 1 Strategy to investigate efficacy of AIs in lung tumors in Kras
mice were intranasally inhaled with Adeno-Cre and monitored at 8 wks aft
All the remaining mice were randomized into groups for treatment with A
administration when majority of animals develop malignant lesions in the
were histologically analyzed. B Representative Images of lung lesions at 8 a
isolated from a wild type mouse.formation and progression in the lung (Figure 1B). All
the remaining mice were randomized into treatment
groups and treated with vehicle, PF-210, axitinib and
sunitinib for about 8 weeks. Upon termination of the
study, lung tissues were analyzed for tumor lesions
using H&E staining (Figure 2). Compared to vehicle-
treated group, there was a significant reduction in lung
lesion in all the three drugs treated groups. To further
understand mechanism of action of AIs, we classified
lung lesions into three categories including hyperpla-
sia, benign neoplasia and malignant (adenocarcinoma).
Detailed pathology analyses of lesions revealed that hy-
perplastic lesions were not significantly affected by AIs
compared to control-treated animals (Figure 3A).
However, the percentage of benign neoplastic lesions











G12D-LSL. A To investigate efficacy of AIs in lung tumors in KrasG12D-LSL,
er inhalation by histology analyses of few lungs from the recipients.
Is (PF-210, axitinib and sunitinib) at 14 wks after Adeno-Cre
lung. At 8 weeks after treatment, all the lungs from the treated mice




Figure 2 AIs suppress growth of advanced lesions in lung tumors in KrasG12D-LSL mice. As described in Figure 1, KrasG12D-LSL tumor bearing
mice were treated for 8 wks with AIs. Treatments started at 14 wks post administration of Adeno-Cre. At the end of study, all the lung tissues
were isolated from the recipients and were analyzed using H&E staining. Images are the representative of each treatment.
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50%) compared to vehicle-treated mice. Finally malig-
nant lesions were significantly (p < 0.01) inhibited by
all the AIs. Additionally we investigated percentage of
mice carrying the above-mentioned lesions (Figure 3B).
Irrespective of the type of treatment, all mice carried
hyperplastic lesions. While all mice treated with
axitinib or sunitinib carried benign neoplasia, only 40%
of PF-210 treated animals carried these lesions indicat-
ing the potency of this compound. Finally all three AIs
reduced frequency of malignant lesions by at least 50%
in treated mice (Figure 3B). Overall, two types of
analyses (percentage of lesions in the lung and percent-
age of mice carrying specific lesion) indicate that AIs
specifically target advanced lesions (malignant or
adenocarcinoma).
Components of vasculature and stroma are targeted by AIs
To further investigate tumor vasculature, we stained
lung tissues with different markers such as CD31 and
desmin to stain endothelial cells and smooth musclecells respectively [16]. Vasculature analysis by CD31
staining showed high density of tumor blood vessels in
adenoma and adenomacarcinoma lesions in the vehicle
group (Figure 4). Moreover, these vessels were desmin
positive indicative of a mature vasculature in these le-
sions. In contrast, tumor lesions in AI treated groups
had less number of blood vessels further suggesting
that vasculature is the main target of these AIs. Add-
itionally, vasculature was found to be more fragmented
compared to the blood vessels in vehicle treated mice.
Similar to CD31 staining, all three AIs (especially
PF-210 and axitinib) targeted smooth muscle cells
suggesting that not only blood vessels but also other
components of vasculature are affected. . We also in-
vestigated the effects of AIs on the expression of
VEGFR1 and VEGFR2 which play an important role in
angiogenesis and tumor progression [1]. High levels of
VEGFR1 was observed on tumor cells in vehicle
treated mice (Figure 4) that is consistent with the ex-
pression of VEGFR1 on tumor cells isolated from Kras
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Figure 3 Benign neoplasia and malignant lesions are targeted
by AIs. A lung lesions were divided into three groups including
hyperplasia, benign neoplasia and malignant as described [15].
Hyperplastic and benign neoplasia comprise majority of lesions in
this model followed by malignant lesions. While percentage of
hyperplastic lesions has not significantly changed in any of the AIs
treatment, while PF-210 treatment significantly reduced the
percentage of benign andenoma lesions. Axitinib and sunitinib also
targeted benign adenoma lesions. All the AIs consistently targeted
percentage of malignant lesions in the lungs. B Analysis of
percentage of mice carrying each lesion in each treatment was
consistent with the above finding. All the treated mice carried
hyperplasia and, with the exception of PF-210, benign neoplasia
lesions. Percentage of mice carrying malignant lesions was
significantly reduced in all the mice treated with AIs. Asterisks
indicate significant difference (p < 0.05) when comparing lesions in
AI treated mice vs. corresponding vehicle-treated animals.
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inhibited VEGFR1 expression on tumor cells (Figure 4).
Compared to vehicle treated tumors that expressed
abundant levels of VEGFR2 on blood vessels, all three
AIs inhibited VEGFR2 expression on the tumor vascu-
lature further providing a mechanism for the anti-
angiogenic activity of these compounds. Overall, these
results suggest that inhibition of angiogenesis is the
main mechanism by which AIs suppress growth of be-
nign and malignant lesions in this model of NSCLC.Tumor associated macrophages (TAMs) are a key
component of tumor microenvironment and have been
implicated in tumor progression and angiogenesis. It
has been shown that NSCLC patients with higher
density of TAMs have lower median relapse-free
survival (7 months) compared to patients whose tumors
had lower density of TIMs (26 months survival) [18].
Macrophage staining (using F4-80) indicated infiltration
of these TAMs in the lung in vehicle treated mice
(Figure 4). Treatment with AIs particularly sunitinib
and axitinib was associated with lower density of
TAMs further suggesting an additional mechanism for
anti-tumor efficacy of AIs in KrasG12D-LSL lung tumors.Discussion
This study reports anti-tumor efficacy of three differ-
ent RTKIs including PF-210, axitinib and sunitinib in
spontaneous tumors in lung in KrasG12D-LSL GEMMs.
The high failure rate of clinical trials in late stage can-
cer patients warrants development of mouse tumor
models which are more relevant to the human diseases.
GEMMs, carrying genetic alterations similar to what is
observed in cancer patients, might represent a more
relevant tumor model to predict clinical outcome.
The VEGF signaling pathway is one of the major sig-
naling pathways in tumor angiogenesis in many cancers.
An anti-VEGF monoclonal antibody, bevacizumab, has
been approved in combination with chemotherapy for
the treatment of NSCLC [19]. Bevacizumab is the first
targeted agent to improve survival in advanced-stage
NSCLC patients when combined with first-line chemo-
therapy. In the present study, we use sunitinib, axitinib,
PF-210 all of which targeting VEGFR signaling pathway
with different pharmacokinetic and pharmacodynamic
properties [7,20]. Our results show that reduction of ma-
lignant lesions in lungs is the common and consistent
theme among all the above compounds. Progression of ma-
lignant lesions prior to diagnosis and treatment are the
major contributors to low survival rate in NSCLC patients
[18]. Lack of efficacy of these agents in hyperplastic le-
sions indicate that angiogenesis may not play a signifi-
cant role in growth of pre-neoplastic lesions lung
tumors in KrasG12D-LSL GEMMs. Additionally while
sunitinib is a multi-targeting RTKIs, our data indicate
that, at clinical dose, targeting PDGFR-β, KIT and
CSF1-R does not provide additional efficacy compared
to PF-210 and axitinib which are selective inhibitors of
VEGF. These data once again signifies the role of
VEGF as a key regulator of tumor angiogenesis in a
preclinical model of NSCLC. PF-210 showed superior
efficacy in suppressing benign neoplasia lesions com-
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Figure 4 Tumor vasculature and components of stroma in lung tumors are targeted by anti-angiogenesis. Formalin fixed paraffin
embedded lung sections (5 μm) stained with anti-CD31 (endothelial cells), anti-desmin (smooth muscle cells), anti-F4-80 (macrophages), anti-
VEGFR1 and anti-VEGFR2 as described in the materials and methods. The slides were scanned on Nanozoomer instrument using 20×
magnification. Irrespective of treatment, AIs treated lungs showed lower CD31 and desmin density. F4-80 staining in vehicle treated mice showed
greater infiltration of macrophages. However, AIs particularly axitinib and sunitinib significantly reduced macrophage infiltration in the tumors. AIs
had differential effects on VEGFR1 and VEGFR2 expression since all treatments reduced VEGFR2 expression in the tumor vasculature, VEGFR1
expression was mainly inhibited by PF-210 and sunitinib. Pictures are the representative images of each staining from each treatment.
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tion of PF-210.
Histopathological analysis showed that all these AIs
target tumor vasculature to inhibit growth of malignant
lesions. Moreover, most of the tumor blood vessels in
treated mice lacked smooth muscle cell coverage
suggesting a role for VEGF in establishment of a cross
talk between smooth muscle cells and endothelial cells.
Furthermore, AI- treated mice had lower number of
TAMs compared to the vehicle treated animals
suggesting that these cells may play a proangiogenic
role in this model [21]. Future studies will determine if
AIs alter homing of macrophages to the tumors or are
directly targeting them. In addition, further investiga-
tion is warranted to understand pharmacokinetics andpharmacodynamics of these compounds in the tumors
which may describe differences in the mechanism of
action of AIs in the current study.Conclusion
Our data indicate that small molecule inhibitors of
VEGF pathway suppress growth of adenocarcinoma le-
sions in a NSCLC model of KrasG12D-LSL GEMM by
targeting components of tumor vasculature and stroma.Competing interests
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